NOVN.CH

113.5

+0.12%↑

LONN.CH

488.9

+1.47%↑

SDZ.CH

63.4

+0.54%↑

STMN.CH

84.44

-0.05%↓

BANB.CH

68.75

+0.95%↑

NOVN.CH

113.5

+0.12%↑

LONN.CH

488.9

+1.47%↑

SDZ.CH

63.4

+0.54%↑

STMN.CH

84.44

-0.05%↓

BANB.CH

68.75

+0.95%↑

NOVN.CH

113.5

+0.12%↑

LONN.CH

488.9

+1.47%↑

SDZ.CH

63.4

+0.54%↑

STMN.CH

84.44

-0.05%↓

BANB.CH

68.75

+0.95%↑

NOVN.CH

113.5

+0.12%↑

LONN.CH

488.9

+1.47%↑

SDZ.CH

63.4

+0.54%↑

STMN.CH

84.44

-0.05%↓

BANB.CH

68.75

+0.95%↑

NOVN.CH

113.5

+0.12%↑

LONN.CH

488.9

+1.47%↑

SDZ.CH

63.4

+0.54%↑

STMN.CH

84.44

-0.05%↓

BANB.CH

68.75

+0.95%↑

Search

Roche Holding AG

Deschisă

SectorSănătate

330.2 -0.06

Rezumat

Modificarea prețului

24h

Curent

Minim

328.4

Maxim

333.4

Indicatori cheie

By Trading Economics

Venit

1.8B

5.5B

Vânzări

15B

31B

P/E

Medie Sector

20.599

60.328

Randament dividend

2.95

Marjă de profit

17.892

Angajați

103,249

EBITDA

5.1B

12B

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.95%

2.24%

Statistici piață

By TradingEconomics

Capitalizare de piață

-26B

263B

Deschiderea anterioară

330.26

Închiderea anterioară

330.2

Sentimentul știrilor

By Acuity

50%

50%

141 / 348 Clasament în Healthcare

Roche Holding AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 apr. 2026, 07:46 UTC

Câștiguri

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 apr. 2026, 05:40 UTC

Câștiguri

Roche Backs Full-Year View as Quarterly Sales Rise

9 mar. 2026, 16:43 UTC

Principalele dinamici ale pieței

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 mar. 2026, 15:44 UTC

Principalele dinamici ale pieței

Correction to Roche Shares Article

9 mar. 2026, 09:51 UTC

Principalele dinamici ale pieței

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 mar. 2026, 09:24 UTC

Principalele dinamici ale pieței

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29 ian. 2026, 10:07 UTC

Câștiguri

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 ian. 2026, 07:07 UTC

Câștiguri

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

23 apr. 2026, 08:10 UTC

Market Talk
Câștiguri

Roche Reports In Line Sales Figures -- Market Talk

23 apr. 2026, 05:04 UTC

Câștiguri

Roche Backs 2026 View

23 apr. 2026, 05:04 UTC

Câștiguri

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 apr. 2026, 05:03 UTC

Câștiguri

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 apr. 2026, 05:02 UTC

Câștiguri

Roche 1Q Group Sales Up 6% at Constant Currency

23 apr. 2026, 05:02 UTC

Câștiguri

Analysts Saw Roche 1Q Sales at CHF14.73B

23 apr. 2026, 05:01 UTC

Câștiguri

Roche 1Q Sales CHF14.72B

10 apr. 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 apr. 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11 mar. 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 mar. 2026, 09:43 UTC

Acțiuni populare

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 mar. 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 mar. 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 mar. 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 ian. 2026, 11:40 UTC

Market Talk
Câștiguri

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 ian. 2026, 06:05 UTC

Câștiguri

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 ian. 2026, 06:04 UTC

Câștiguri

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 ian. 2026, 06:03 UTC

Câștiguri

Roche Issues 2026 View

29 ian. 2026, 06:02 UTC

Câștiguri

Analysts Saw 2025 Core EPS at CHF19.70

29 ian. 2026, 06:02 UTC

Câștiguri

Roche: 2025 Core EPS CHF19.46

29 ian. 2026, 06:01 UTC

Câștiguri

Analysts Had Seen 2025 Sales At CHF61.47B

29 ian. 2026, 06:01 UTC

Câștiguri

Roche 2025 Sales CHF61.52B

Comparație

Modificare preț

Roche Holding AG Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

141 / 348 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat